1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Parallels in Development of Monoclonal Antibodies and Therapeutic Vaccines Prompt Industry Optimism

Although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies, notes Kalorama.

 
PRLog - Oct. 25, 2010 - NEW YORK -- For anyone thinking the idea of vaccines for cancer too fantastic to make a viable market, healthcare market research publisher Kalorama Information suggests a look at the history of another drug category – monoclonal antibodies.  Parallels between the emerging therapeutic vaccines industry and the history of the monoclonal antibodies industry can be seen, according to Kalorama. In the case of monoclonal antibodies, their eventual long-awaited success was driven by technology evolution from murine to chimeric, and ultimately humanized and fully human antibodies. Now the industry has exceeded $10 billion in annual sales, and is expected to continue to grow rapidly.

“At the time, not everyone thought mAbs would be accepted,” said Melissa Elder, analyst for Kalorama Information.  “Now they are thriving.’

As covered in their report, Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition, although the therapeutic vaccine market has experienced a range of setbacks and disappointments, technological evolution should ultimately enable therapeutic vaccines to make similar commercial breakthroughs as monoclonal antibodies. Scientists may be able to develop improved vaccines from a more complete understanding of the interactions between the immune system and cancer cells.

A new wave of 'off-the-shelf' generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines. As clinical experience mounts, new antigen delivery technologies appear and combination vaccines gain favor, the prospect of new non-toxic therapies for cancer and HIV gets closer to being reality.    

More information on cancer vaccines, including potential products and forecasts for each category of cancer, can be found at: http://www.kaloramainformation.com/Emerging-Cancer-Vaccin....

# # #

About Kalorama Information
Kalorama Information (www.kaloramainformation.com) supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/KaloramaInfo.

Please direct all media inquiries to:
Andrea Hiller
Marketing Manager
(212) 807-2673
press@kaloramainformation.com
www.kaloramaInformation.com

--- End ---

Click to Share

Contact Email:
***@kaloramainformation.com Email Verified
Source:Kalorama Information
Phone:(212) 807-2673
Zip:10016
City/Town:New York City - New York - United States
Industry:Medical, Health, Biotech
Tags:Health, Medical, Healthcare, physician, doctor, clinics, hospital, vaccines, antibodies, monoclonal, cancer, science
Last Updated:Oct 12, 2011
Shortcut:prlog.org/11023527
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share